Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma

Hiroshi Yokouchi, Kenji Chamoto, Daiko Wakita, Koichi Yamazaki, Hiroki Shirato, Tsuguhide Takeshima, Hirotoshi Dosaka-Akita, Masaharu Nishimura, Zhang Yue, Hidemitsu Kitamura, Takashi Nishimura

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Mice bearing established Lewis lung carcinoma (LLC) expressing model tumor antigen, ovalbumin (OVA) (LLC-OVA) marginally responded to local radiotherapy, but none of the mice was cured. In contrast, treatment of the tumor-bearing mice with intratumoral injection of tumor-specific T helper type 1 (Th1) cells and tumor antigen (OVA) after radiotherapy dramatically prolonged the survival days and induced complete cure of the mice at high frequency (80%). Radiation therapy combined with Th1 cells or OVA alone showed no significant therapeutic activity against LLC-OVA. Such a strong therapeutic activity was not induced by intratumoral injection of Th1 cells plus OVA. Compared with other treatment, radiation therapy combined with Th1 cells and OVA was superior to induce the generation of OVA/H-2b tetramer+ tumor-specific cytotoxic T lymphocyte (CTL) with a strong cytotoxicity against LLC-OVA in draining lymph node (DLN). Moreover, the combined therapy is demonstrated to inhibit the growth of tumor mass, which grew at contralateral side. These results indicated that radiotherapy combined with Th1 cell/vaccine therapy induced a systemic antitumor immunity. These findings suggested that combination therapy with radiotherapy and Th1 cell/vaccine therapy may become a practical strategy for cancer treatment.

Original languageEnglish (US)
Pages (from-to)533-540
Number of pages8
JournalClinical and Experimental Metastasis
Issue number7
StatePublished - Nov 2007


  • Draining lymph node
  • Immunotherapy
  • Irradiation
  • Lung cancer
  • Th1 cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma'. Together they form a unique fingerprint.

Cite this